Mochamad Yusuf Alsagaff, - and Eka Prasetya Budi Mulia, - and Irma Maghfirah, - and Kevin Luke, - and David Nugraha, - and Dita Aulia Rachmi, - and Imanita Septianda, - and Maya Qurota A'yun, - (2021) Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15 (5). ISSN 1871-4021

	Text (Artikel) 9. Association of Calcium Channel Blocker Use on Clinical Outcome of Covid 19 A Meta-analysis_DMS CRR 2021.pdf Download (1MB)
	Text (Bukti Korespondensi) 9. Korespondensi.pdf Download (101kB)
	Text (Peer Review) karil 9.pdf Download (97kB)
	Text (Similariti) 9. Turnitin.pdf Download (3MB)

Abstract

Aims This meta-analysis aims to analyze the association of calcium channel blocker (CCB) use with COVID-19 clinical outcomes. Methods PubMed, ProQuest, Science Direct, Scopus, and medRxiv databases were searched systematically in a limited period. The primary outcome was mortality. Results A total of 119,298 patients from 31 eligible studies were included. Pooled analysis of the random-effect model revealed CCB was not associated with reduced mortality (OR = 1.21 [95%CI: 0.98–1.49], p = 0.08). Interestingly, subgroup analysis in hypertensive patients revealed significantly reduced mortality (OR = 0.69 [95%CI: 0.52–0.91], p = 0.009). Conclusion CCB usage was not associated with the outcome of COVID-19. However, CCB was associated with a decreased mortality rate in hypertensive COVID-19 patients.

Actions (login required)

View Item